Caladrius Biosciences

387 articles with Caladrius Biosciences

• Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021

  1/6/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o

• Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio UpdateProgram strategy and prioritization supports projection of available capital through 2021

  12/14/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. “The Company evaluated its current and proposed devel

• Caladrius Biosciences to Webcast Live at Life Sciences Investor ForumCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

  12/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th.

• Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerThe Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

  11/17/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius.

• Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020

  11/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020.

• Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November

  11/4/2020

  - Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. November 11-16, 2020 LSX Virtual Inv€$tival Showcase November 17-19, 2020 Jefferies Virtual London Healthcare Conferenc e Novemb

• Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors

  11/2/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles

• Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time

  10/29/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that the Company will report its third quarter financial results for the three and nine months ended September 30, 2020 on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. Live Conference Call and We

• Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°

  10/21/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°

• 

  Clinical Catch-Up: October 12-16

  10/19/2020

  It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: October 13

  10/13/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.

• Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

  10/8/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health.

• Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

  10/7/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will present at the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa, being held virtually on October 12-16, 2020. T

• Caladrius Biosciences to Present at the BIO Investor Forum Digital

  10/6/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO I

• Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th

  9/14/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020.

• Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum

  9/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmark’s 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020.   

• Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan

  9/9/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12,

• Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  9/8/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Presentation Details: Date & Time: Tuesday, Septembe

• Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020

  9/3/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020. Title: Repair of the microcirculation reverses ischemic tissue damage Presenter: Dougl

• Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time

  8/27/2020

  Caladrius Biosciences, Inc. today announced that management has been invited to present at the LD 500 virtual investor conference being held September 1-4, 2020.